BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation announced that pharmaceutical, diagnostic and biotechnology senior executive Stephen J. Sullivan joined its Board of Directors. PHT is the leading provider of innovative technology systems used to collect patient-driven eData for clinical research.
PHT President, CEO and Director Philip Lee said, "It is a pleasure to welcome Steve Sullivan to the PHT Board of Directors. Steve is a proven leader in guiding and advising public, private and venture-backed companies in the clinical trial services market sector. His unique knowledge of the industry and experience growing successful companies is invaluable to PHT as the company enters a new stage of rapid growth."
Mr. Sullivan is Founder of CRO Advisors LLC, a consulting practice that advises CRO leaders, partners and investors to make and implement strategic decisions. Previously Mr. Sullivan was President, CEO and Director of Harlan Laboratories, a pre-clinical CRO and Research Models and Services Company. Prior to Harlan, Mr. Sullivan was a Senior Vice President at Covance, and President of the Central Labs Group and Clinical Support Services. Earlier, Mr. Sullivan held management positions at Xenometrix; Abbott Laboratories; Dart & Kraft, Inc.; Baxter International; C. R. Bard, Inc.; and, Johnson & Johnson.
PHT is the leader in capturing patient experience data in clinical trials and there is increased demand from CROs and trial sponsors for these services. Mr. Sullivan said, "I am delighted to join this talented team of executives and board members who are committed to build upon PHT's leadership position in ePRO."
Mr. Sullivan is non-executive Chairman of the Boards of Molecular Imaging Research, Inc. and BioreclamationIVT, Inc. and is on the board of PDI, Inc.
Mr. Sullivan received his MBA from Rutgers University and BS from the University of Dayton. He has been an Adjunct Professor at J.L. Kellogg Graduate School. Mr. Sullivan was a U.S. Marine Corps officer and Vietnam veteran.
About PHT Corporation
PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial programs with greater confidence, ease and accuracy. Proven PHT electronic clinical outcome assessment (eCOA) Systems collect patient-driven eData via smartphones, tablets and the web. This data, available viaStudyWorks™ online reporting portal, provides sponsors and clinicians with a real time window into how patients feel and function. PHT has helped trial sponsors collect patient-driven eData in 650+ global trials resulting in 16+ regulatory approvals. PHT Clinical Science and Consulting offers the scientific, regulatory, and technological expertise today's eCOA market demands and patients deserve. Visit www.phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Twitter, Google+ and YouTube.
For PHT Corporation
Brenda Nashawaty, 617-688-3253